GLP-1, peptides, and hair loss: separating signal from noise

What did @elizabethsglp1journey actually say?

The creator describes losing 17 pounds over 10 weeks on a GLP-1, then adding GHK-Cu and NAD to support "hair, skin and nails." She calls this "literally stacking three peptides" and frames her telehealth provider as a quality-focused middle ground, emphasizing 503A compounding, purity certificates, US manufacturing, and cold-chain shipping. She encourages viewers to DM her for provider details.

A few things stand out immediately. First, NAD (nicotinamide adenine dinucleotide) is not a peptide. It's a coenzyme. Calling it one isn't a minor slip, it's a factual error that matters when you're positioning yourself as someone educating a 33,000-person audience. Second, the video is structured as a provider referral, not just a personal story, which raises disclosure questions regardless of how genuine the experience is.

Does the science back this up?

The GLP-1 weight loss claim is the strongest here. Seventeen pounds in 10 weeks is plausible and consistent with clinical trial data. The GHK-Cu hair claim has some biological basis but is far less settled. The NAD framing is where things get murkier.

On GLP-1s: semaglutide trials like the STEP 1 study (Wilding et al., 2021, NEJM) showed average weight loss of roughly 15% body weight over 68 weeks. Ten weeks of 17 pounds is on the higher end of early responders but not implausible for someone with higher starting weight or a responsive phenotype.

On GHK-Cu: this copper peptide has shown some promise in preclinical and in vitro studies for wound healing and skin remodeling (Pickart et al., 2015, Journal of Aging Science), and a small number of studies suggest effects on follicular activity. But robust, randomized human trials specifically for hair growth are sparse. The evidence is suggestive, not conclusive.

On NAD: precursor supplementation (like NMN or NR) has shown some metabolic and cellular repair signals in animal models and early human trials (Yoshino et al., 2021, Science), but direct NAD infusion or supplementation for general "wellness stacking" is still being studied. Calling it a peptide misrepresents the compound entirely.

What did they get wrong (or right)?

Credit where it's due: the creator is correct that 503A compounding pharmacies produce patient-specific formulations, and that this differs from mass-manufactured generics. The point about "a mixture that is specific for your body type" roughly describes the intent of 503A compounding, even if it overstates the individualization in practice.

The cold-chain shipping point is also legitimate. Peptides like GHK-Cu and certain GLP-1 formulations are temperature-sensitive, and shipping on ice is a real quality consideration, not just marketing language.

What she got wrong: NAD is not a peptide. This is a basic biochemistry error. GHK-Cu is a tripeptide, GLP-1 receptor agonists are peptide-based drugs, but NAD is a dinucleotide coenzyme. Grouping them under "three peptides" muddies the category for viewers trying to understand what they're actually taking.

She also implies that 503A compounding guarantees no "additives, fillers, heavy metals." That's not what 503A status guarantees. It means the pharmacy must comply with USP standards and state board regulations, but it does not automatically mean every batch is tested for heavy metals. Purity certificates vary by pharmacy and should be requested specifically.

What should you actually know?

If you're considering any of these compounds, the regulatory and safety picture matters more than any one creator's experience. GLP-1 receptor agonists prescribed through legitimate telehealth and compounded at a licensed 503A pharmacy can be a reasonable pathway, but compounded semaglutide is not the same as brand-name Ozempic or Wegovy, and the FDA has flagged concerns about compounded GLP-1 products, including dosing errors and variable potency.

GHK-Cu is not FDA-approved for any indication. It's available through compounding channels, and the existing evidence is preliminary. Anyone using it for hair loss should understand they are using a compound with limited human trial data, not an approved treatment.

The DM-for-provider-info structure in this video is a common pattern in telehealth affiliate marketing. That doesn't mean the provider is bad, but it does mean viewers should verify independently rather than relying on a referral from someone who may have a financial relationship with the platform. Ask any telehealth provider directly: What pharmacy do you use? Can I see the COA for my specific compound? Is my prescribing physician licensed in my state?